Holen Sie sich die Stockscreener-App
10.83
0.28%
-0.0519
Schlusskurs vom Vortag:
$10.88
Offen:
$10.78
24-Stunden-Volumen:
89,934
Relative Volume:
0.20
Marktkapitalisierung:
$528.50M
Einnahmen:
$251.00K
Nettoeinkommen (Verlust:
$-87.07M
KGV:
-3.0507
EPS:
-3.5494
Netto-Cashflow:
$-80.18M
1W Leistung:
-4.08%
1M Leistung:
-3.74%
6M Leistung:
+90.00%
1J Leistung:
+290.25%
1-Tages-Spanne:
$10.76
$11.15
1-Wochen-Bereich:
$10.70
$11.35
52-Wochen-Spanne:
$2.22
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Firmenname
Artiva Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 267-4467
Adresse
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
10.81 | 531.92M | 251.00K | -87.07M | -80.18M | -3.5494 |
VRTX
Vertex Pharmaceuticals Inc
|
521.29 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.12 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.36 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.10 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Eingeleitet | Jefferies | Buy |
| 2024-08-13 | Eingeleitet | Needham | Buy |
| 2024-08-13 | Eingeleitet | TD Cowen | Buy |
| 2024-08-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
ARTV: Pivotal phase III trial for refractory RA advances, with robust enrollment and data updates expected - TradingView
Artiva Biotherapeutics CEO Aslan Fred Offloads 61,888 Shares at $11.16 on September 3, 2026 (NASDAQ: ARTV) - Kalkine Media
Artiva Biotherapeutics CTO Horan Christopher Disposes of 10,366 Shares at $11.16 Each (NASDAQ: ARTV) - Kalkine Media
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com Canada
Artiva initiates phase 3 trial for refractory arthritis therapy - Investing.com
Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis - Quiver Quantitative
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Yahoo! Finance Canada
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CEO Fred Aslan Sells 61,888 Shares in Tax-Related Sell-to-Cover Transaction - Kalkine Media
Artiva Biotherapeutics COO Jennifer Bush Executes Share Sale for Tax Withholding Purposes - Kalkine Media
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewswire
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Australia
Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan - Kalkine Media
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
ARTV Q2 2026 Earnings: Slightly Narrower Loss Delivers a Modest BeatOperating Income Trends - vinanet.vn
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan - Bitget
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower Loss of $0.63 per Share, But Stock Slips 0.35%Debt Analysis Report - vinanet.vn
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
Artiva Biotherapeutics (ARTV) Edges Down 0.44% to $11.22, Trading Between Key Support and ResistanceVolatility Smile - dars.gov.et
Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58 - Moomoo
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63 - webull.com
Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanks
Artiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target - TipRanks
Certain Restricted Stock Units of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Certain Stock Options of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Artiva Biotherapeutics (NASDAQ:ARTV) Announces Quarterly Earnings Results - MarketBeat
Artiva Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Artiva Biotherapeutics reports Q2 2026 net loss $25.0M, cash $349.4M to fund operations into 2029 - TradingView
FDA RMAT designation for AlloNK plus rituximab boosts Artiva Biotherapeutics, Inc. clinical progress - Traders Union
Artiva Biotherapeutics stock surges on positive trial data By Investing.com - Investing.com Nigeria
Form DEF 14A Artiva Biotherapeutics For: 3 August By Investing.com - Investing.com Nigeria
Ra capital management, 10% owner, acquires $455,725 Artiva stock - Investing.com
Form 4 Artiva Biotherapeutics Inc For: 1 August By Investing.com - Investing.com UK
Ra capital management, 10% owner, acquires $455,725 Artiva stock By Investing.com - Investing.com Canada
Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $247,693.92 in Stock - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ra capital management director buys $412,776 in Artiva Biotherapeutics By Investing.com - Investing.com Nigeria
Form 4 Artiva Biotherapeutics Inc For: 28 July By Investing.com - Investing.com Canada
Artiva Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ARTV - TradingView
RA Capital Management Boosts Artiva Biotherapeutics Stake with $412,000 Stock Acquisition - Kalkine Media
Artiva Biotherapeutics Inc (ARTV) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Finanzdaten der Artiva Biotherapeutics Inc-Aktie (ARTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Artiva Biotherapeutics Inc-Aktie (ARTV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Horan Christopher | Chief Tech Operations Officer |
Sep 03 '26 |
Sale |
11.16 |
10,366 |
115,638 |
283,084 |
| Bush Jennifer | COO, CLO, Compliance Officer |
Sep 03 '26 |
Sale |
11.16 |
8,391 |
93,606 |
329,529 |
| Banerjee Subhashis | Chief Medical Officer |
Sep 03 '26 |
Sale |
11.16 |
1,100 |
12,271 |
140,947 |
| Aslan Fred | Chief Executive Officer |
Sep 03 '26 |
Sale |
11.16 |
61,888 |
690,392 |
1,473,194 |
| Banerjee Subhashis | Chief Medical Officer |
Aug 27 '26 |
Option Exercise |
1.92 |
5,306 |
10,188 |
150,269 |
| Banerjee Subhashis | Chief Medical Officer |
Aug 27 '26 |
Sale |
12.01 |
8,222 |
98,736 |
142,047 |
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):